Abstract 329P
Background
Breast cancer (BC) radiotherapy (RT) may induce lung damage ranging from radiological changes only to respiratory failure. The evidence of long-term radiation fibrosis (RF) and its impact on lung function and patients reported dyspnea is scarce. The aim of the present study was to evaluate lung function from before RT to up to 12 years after treatment and identify predictors for long-term RF and reduced lung function.
Methods
BC patients (n=250) referred to postoperative RT (2 Gy x 25) were enrolled in a prospective cohort study from February 2007 to October 2008. All assessments were conducted through clinical controls before RT (baseline), at 3, 6 and 12 months and at long-term follow- up ranging from 7-12 years after RT. Lung function was assessed by the pulmonary function tests (PFT) Vital capacity (VC), Forced Expiratory volume in 1second (FEV1), Forced Vital Capacity (FVC) and diffusion capacity for carbon monoxide (DLCO). RF was diagnosed by High Resolution Computer Tomography scans and graded in accordance with the CTCAE version 3.0 criteria. Patient reported dyspnea was assessed by the EORTC QLQ-C30.
Results
VC, FVC, FEV1 and DLCO declined at 3 months after RT and remained low at long-term follow-up except for DLCO which increased up to 12 years after RT. VC, FEV1, and FVC changes from baseline differed between patients treated with chemotherapy and those not treated with chemotherapy. FEV1 changes from baseline differed between locoregional and local radiated patients. A decline in VC, FEV1, and FVC 3 months after RT predicted a decline in PFT up to 12 years (p=0.020, p=0.004, and p=0.020, respectively). At long-term follow-up age was the only patient and treatment-related factor associated with RF (p=0.021). RF was observed in 144 patients (91%), of which 129 (81%) had fibrosis Grade 1 and 15 (9%) had fibrosis Grade 2. 61 (35%) patients reported dyspnea, mainly grade 1.
Conclusions
Pulmonary function deteriorated in the first year and up to 12 years after BC RT. An early decline in VC, FVC and FEV1 predicted further decline at long-term follow-up. RT. Chemotherapy and locoregional RT predicted a decrease in PFT in the first year and for up to 12 years after RT. Older age was associated with RF at long-term follow-up. Few patients reported severe dyspnea.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Norwegian University of Science and Technology, Faculty of Medicine.
Funding
The Liaison Committee for education, research and innovation in Central Norway.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
263P - Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data
Presenter: Layal Rached
Session: Poster session 02
264P - Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): Final analysis
Presenter: Sheyda Abdullaeva
Session: Poster session 02
265P - Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: A 10-year dual-center retrospective study
Presenter: Yijun Li
Session: Poster session 02
266P - Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis
Presenter: Francesca Schipilliti
Session: Poster session 02
267P - Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+ early breast cancer: Real-world data from NeoPowER study
Presenter: Fabio Canino
Session: Poster session 02
268P - Evaluating the efficacy of adjuvant capecitabine in triple-negative breast cancer patients with residual disease: A real-world evidence study
Presenter: Min Jeong Kim
Session: Poster session 02
269P - Achieving treatment goals in elderly breast cancer patients with neoadjuvant chemotherapy: A remarkable insight
Presenter: Eda Caliskan Yildirim
Session: Poster session 02
270P - Influence of neoadjuvant chemotherapy-induced short-term amenorrhea on pathologic response and treatment outcome in ER+HER2- breast cancer
Presenter: Seung Eun Lee
Session: Poster session 02
271P - First clinical demonstration of the predictive value of tissue nanomechanical signature in breast cancer patients in neoadjuvant therapy setting
Presenter: Sara Nizzero
Session: Poster session 02